Dr. Ann Mullally is an Associate Professor of Medicine at Harvard Medical School, a physician-scientist at Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) and an Associate Member at the Broad Institute. Dr Mullally’s laboratory studies the genetics, biology and therapy of myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). Using mouse models, functional genomics and proteomics as well as standard cellular and molecular biology techniques, the lab has investigated the key molecular genetic events that drive the development of MPN. Recently, the lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN. The lab has also worked extensively on the JAK2V167F mutation, the molecular dependencies of MPN stem cells and the biology of myelofibrosis. Dr. Mullally received her MD from University College Dublin, Ireland, completed residency at Johns Hopkins Hospital and a fellowship in Hematology and Oncology at DFCI. She sees patients with MPN in her clinic at DFCI and is actively involved in all aspects of patient-oriented research. The overarching goal of Dr. Mullally’s research is to advance the understanding of the biology of myeloid blood cancers and to translate this into improved treatment options for patients dealing with these diseases.